PMC:7558333 / 24330-26952
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T54","span":{"begin":182,"end":194},"obj":"Body_part"},{"id":"T55","span":{"begin":947,"end":953},"obj":"Body_part"},{"id":"T56","span":{"begin":1094,"end":1099},"obj":"Body_part"},{"id":"T57","span":{"begin":1252,"end":1268},"obj":"Body_part"},{"id":"T58","span":{"begin":1264,"end":1268},"obj":"Body_part"},{"id":"T59","span":{"begin":1349,"end":1359},"obj":"Body_part"},{"id":"T60","span":{"begin":1440,"end":1450},"obj":"Body_part"},{"id":"T61","span":{"begin":1541,"end":1551},"obj":"Body_part"},{"id":"T62","span":{"begin":1628,"end":1636},"obj":"Body_part"},{"id":"T63","span":{"begin":1898,"end":1905},"obj":"Body_part"},{"id":"T64","span":{"begin":2485,"end":2489},"obj":"Body_part"},{"id":"T65","span":{"begin":2566,"end":2571},"obj":"Body_part"}],"attributes":[{"id":"A54","pred":"fma_id","subj":"T54","obj":"http://purl.org/sig/ont/fma/fma14543"},{"id":"A55","pred":"fma_id","subj":"T55","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A56","pred":"fma_id","subj":"T56","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A57","pred":"fma_id","subj":"T57","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A58","pred":"fma_id","subj":"T58","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A59","pred":"fma_id","subj":"T59","obj":"http://purl.org/sig/ont/fma/fma62860"},{"id":"A60","pred":"fma_id","subj":"T60","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A61","pred":"fma_id","subj":"T61","obj":"http://purl.org/sig/ont/fma/fma62293"},{"id":"A62","pred":"fma_id","subj":"T62","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A63","pred":"fma_id","subj":"T63","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A64","pred":"fma_id","subj":"T64","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A65","pred":"fma_id","subj":"T65","obj":"http://purl.org/sig/ont/fma/fma67498"}],"text":"Table 3 Demographic characteristics and clinical and biological baseline characteristics.\nDemographic Characteristics All Patients (n = 45) No Aspergillosis (n = 30) Aspergillus Colonization (n = 8) Putative/Probable Invasive Aspergillosis (n = 7) p Value\nAge, years 60 (53–71) 59 (54–68) 53 (51–71) 70 (63–75) 0.14\nSexMen Women 32 (71.1)13 (28.9) 21 (70)9 (30) 7 (87.5)1 (12.5) 4 (57.1)3 (42.8) 0.42\nBMI 27 (24.4–31.4) 27.5 (24.7–32.3) 27 (25.2–30.7) 25.2 (23.2–26.4) 0.99\nCurrent smoking 3 (6.7) 2 (4.4) 0 1 (12.5) 0.54\nCoexisting conditions\nAny 31 (68.9) 19 (63) 6 (75) 6 (85.7) 0.47\nDiabetes 17 (37.8) 12 (40) 3 (37.5) 2 (28.6) 0.74\nHypertension 15 (33.3) 7 (23.3) 5 (62.5) 3 (42.9) 0.1\nSolid cancer 1 (2.2) 1 (3.3) 0 0 0.77\nHemopathy 2 (4.4) 1 (3.3) 0 1 (14.3) 0.54\nCardiovascular disease 3 (6.7) 3 (10) 2 (25) 2 (28.6) 0.34\nChronic obstructive pulmonary disease 0 0 0 0 -\nChronic kidney disease 4 (8.9) 2 (6.7) 1 (12.5) 1 (14.3) 0.83\nTemperature (°C) 38 (37–38.9) 37.5 (337–38.4) 38.2 (37.9–39) 38.2 (37.7–38.8) 0.29\nHeart rate (/min) 100 (80–110) 94 (80–110) 104 (100–110) 102 (85–119) 0.63\nSystolic pressure 94 (87–107) 93 (85–105) 103 (100–109) 90 (82–102) 0.34\nWhite blood cell count (109/L) 9.8 (6.8–12.9) 9.7 (6.9–13) 9.9 (7–10.7) 9.9 (6.7–12.9) 0.97\nNeutrophil count (109/L) 7.9 (4.5–10.8) 7 (4.9–10.5) 8.5 (5.2–8.6) 5.6 (3.5–10.4) 0.8\nLymphocyte count (109/L) 0.81 (0.58–1.11) 0.83 (0.53–1.14) 0.7 (0.63–1.1) 0.72 (0.58–0.81) 0.87\nHemoglobin (g/L) 10.8 (9.5–12.5) 10 (9.4–12) 11.8 (10.6–13.6) 11 (10.5–13.6) 0.12\nPlatelet count (109/L) 264 (194–357) 282 (220–364) 244 (184–347) 162 (129–262) 0.12\nTotal bilirubin concentration (µmol/L) 8 (5.5–12) 8.5 (6–12) 11 (9–13) 7 (5.5–8) 0.72\nCreatinine (µmol/L) 81 (53–162) 71 (51–109) 81 (73–173) 101 (82–184) 0.15\nC-reactive protein (CRP) (mg/L) 157 (112–263) 155 (112–265) 112 (102–131) 112 (109–178) 0.03\nRatio of PaO2 to FiO2 152 (100–181) 164 (107–214) 120 (94–214) 136 (72–155) 0.25\nSAPS II score on day 1 42 (31–57) 35 (30–58) 42 (21–55) 43 (35–82) 0.55\nSOFA score on day 1 7 (2–11) 7 (4–10) 5 (2–10) 9 (2–12) 0.76\nData are presented as median (IQR: interquartiles), n (%). P values comparing Aspergillus colonization, invasive aspergillosis and no aspergillosis groups are tested by Kruskal–Wallis (continuous variables) or Chi-square test (categorical variables). Abbreviations: BMI: Body mass index; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment, PaO2: arterial oxygen tension."}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T37","span":{"begin":947,"end":953},"obj":"Body_part"},{"id":"T38","span":{"begin":1094,"end":1099},"obj":"Body_part"},{"id":"T39","span":{"begin":1258,"end":1263},"obj":"Body_part"},{"id":"T40","span":{"begin":2566,"end":2571},"obj":"Body_part"}],"attributes":[{"id":"A37","pred":"uberon_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"A38","pred":"uberon_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A40","pred":"uberon_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"Table 3 Demographic characteristics and clinical and biological baseline characteristics.\nDemographic Characteristics All Patients (n = 45) No Aspergillosis (n = 30) Aspergillus Colonization (n = 8) Putative/Probable Invasive Aspergillosis (n = 7) p Value\nAge, years 60 (53–71) 59 (54–68) 53 (51–71) 70 (63–75) 0.14\nSexMen Women 32 (71.1)13 (28.9) 21 (70)9 (30) 7 (87.5)1 (12.5) 4 (57.1)3 (42.8) 0.42\nBMI 27 (24.4–31.4) 27.5 (24.7–32.3) 27 (25.2–30.7) 25.2 (23.2–26.4) 0.99\nCurrent smoking 3 (6.7) 2 (4.4) 0 1 (12.5) 0.54\nCoexisting conditions\nAny 31 (68.9) 19 (63) 6 (75) 6 (85.7) 0.47\nDiabetes 17 (37.8) 12 (40) 3 (37.5) 2 (28.6) 0.74\nHypertension 15 (33.3) 7 (23.3) 5 (62.5) 3 (42.9) 0.1\nSolid cancer 1 (2.2) 1 (3.3) 0 0 0.77\nHemopathy 2 (4.4) 1 (3.3) 0 1 (14.3) 0.54\nCardiovascular disease 3 (6.7) 3 (10) 2 (25) 2 (28.6) 0.34\nChronic obstructive pulmonary disease 0 0 0 0 -\nChronic kidney disease 4 (8.9) 2 (6.7) 1 (12.5) 1 (14.3) 0.83\nTemperature (°C) 38 (37–38.9) 37.5 (337–38.4) 38.2 (37.9–39) 38.2 (37.7–38.8) 0.29\nHeart rate (/min) 100 (80–110) 94 (80–110) 104 (100–110) 102 (85–119) 0.63\nSystolic pressure 94 (87–107) 93 (85–105) 103 (100–109) 90 (82–102) 0.34\nWhite blood cell count (109/L) 9.8 (6.8–12.9) 9.7 (6.9–13) 9.9 (7–10.7) 9.9 (6.7–12.9) 0.97\nNeutrophil count (109/L) 7.9 (4.5–10.8) 7 (4.9–10.5) 8.5 (5.2–8.6) 5.6 (3.5–10.4) 0.8\nLymphocyte count (109/L) 0.81 (0.58–1.11) 0.83 (0.53–1.14) 0.7 (0.63–1.1) 0.72 (0.58–0.81) 0.87\nHemoglobin (g/L) 10.8 (9.5–12.5) 10 (9.4–12) 11.8 (10.6–13.6) 11 (10.5–13.6) 0.12\nPlatelet count (109/L) 264 (194–357) 282 (220–364) 244 (184–347) 162 (129–262) 0.12\nTotal bilirubin concentration (µmol/L) 8 (5.5–12) 8.5 (6–12) 11 (9–13) 7 (5.5–8) 0.72\nCreatinine (µmol/L) 81 (53–162) 71 (51–109) 81 (73–173) 101 (82–184) 0.15\nC-reactive protein (CRP) (mg/L) 157 (112–263) 155 (112–265) 112 (102–131) 112 (109–178) 0.03\nRatio of PaO2 to FiO2 152 (100–181) 164 (107–214) 120 (94–214) 136 (72–155) 0.25\nSAPS II score on day 1 42 (31–57) 35 (30–58) 42 (21–55) 43 (35–82) 0.55\nSOFA score on day 1 7 (2–11) 7 (4–10) 5 (2–10) 9 (2–12) 0.76\nData are presented as median (IQR: interquartiles), n (%). P values comparing Aspergillus colonization, invasive aspergillosis and no aspergillosis groups are tested by Kruskal–Wallis (continuous variables) or Chi-square test (categorical variables). Abbreviations: BMI: Body mass index; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment, PaO2: arterial oxygen tension."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T136","span":{"begin":146,"end":159},"obj":"Disease"},{"id":"T137","span":{"begin":222,"end":244},"obj":"Disease"},{"id":"T138","span":{"begin":231,"end":244},"obj":"Disease"},{"id":"T139","span":{"begin":618,"end":626},"obj":"Disease"},{"id":"T140","span":{"begin":673,"end":685},"obj":"Disease"},{"id":"T141","span":{"begin":738,"end":744},"obj":"Disease"},{"id":"T142","span":{"begin":822,"end":844},"obj":"Disease"},{"id":"T143","span":{"begin":886,"end":923},"obj":"Disease"},{"id":"T144","span":{"begin":906,"end":923},"obj":"Disease"},{"id":"T145","span":{"begin":939,"end":961},"obj":"Disease"},{"id":"T146","span":{"begin":947,"end":961},"obj":"Disease"},{"id":"T148","span":{"begin":2318,"end":2340},"obj":"Disease"},{"id":"T149","span":{"begin":2327,"end":2340},"obj":"Disease"},{"id":"T150","span":{"begin":2348,"end":2361},"obj":"Disease"}],"attributes":[{"id":"A136","pred":"mondo_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A137","pred":"mondo_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A144","pred":"mondo_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A145","pred":"mondo_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/MONDO_0005300"},{"id":"A146","pred":"mondo_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/MONDO_0001343"},{"id":"A147","pred":"mondo_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/MONDO_0005240"},{"id":"A148","pred":"mondo_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A149","pred":"mondo_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A150","pred":"mondo_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"}],"text":"Table 3 Demographic characteristics and clinical and biological baseline characteristics.\nDemographic Characteristics All Patients (n = 45) No Aspergillosis (n = 30) Aspergillus Colonization (n = 8) Putative/Probable Invasive Aspergillosis (n = 7) p Value\nAge, years 60 (53–71) 59 (54–68) 53 (51–71) 70 (63–75) 0.14\nSexMen Women 32 (71.1)13 (28.9) 21 (70)9 (30) 7 (87.5)1 (12.5) 4 (57.1)3 (42.8) 0.42\nBMI 27 (24.4–31.4) 27.5 (24.7–32.3) 27 (25.2–30.7) 25.2 (23.2–26.4) 0.99\nCurrent smoking 3 (6.7) 2 (4.4) 0 1 (12.5) 0.54\nCoexisting conditions\nAny 31 (68.9) 19 (63) 6 (75) 6 (85.7) 0.47\nDiabetes 17 (37.8) 12 (40) 3 (37.5) 2 (28.6) 0.74\nHypertension 15 (33.3) 7 (23.3) 5 (62.5) 3 (42.9) 0.1\nSolid cancer 1 (2.2) 1 (3.3) 0 0 0.77\nHemopathy 2 (4.4) 1 (3.3) 0 1 (14.3) 0.54\nCardiovascular disease 3 (6.7) 3 (10) 2 (25) 2 (28.6) 0.34\nChronic obstructive pulmonary disease 0 0 0 0 -\nChronic kidney disease 4 (8.9) 2 (6.7) 1 (12.5) 1 (14.3) 0.83\nTemperature (°C) 38 (37–38.9) 37.5 (337–38.4) 38.2 (37.9–39) 38.2 (37.7–38.8) 0.29\nHeart rate (/min) 100 (80–110) 94 (80–110) 104 (100–110) 102 (85–119) 0.63\nSystolic pressure 94 (87–107) 93 (85–105) 103 (100–109) 90 (82–102) 0.34\nWhite blood cell count (109/L) 9.8 (6.8–12.9) 9.7 (6.9–13) 9.9 (7–10.7) 9.9 (6.7–12.9) 0.97\nNeutrophil count (109/L) 7.9 (4.5–10.8) 7 (4.9–10.5) 8.5 (5.2–8.6) 5.6 (3.5–10.4) 0.8\nLymphocyte count (109/L) 0.81 (0.58–1.11) 0.83 (0.53–1.14) 0.7 (0.63–1.1) 0.72 (0.58–0.81) 0.87\nHemoglobin (g/L) 10.8 (9.5–12.5) 10 (9.4–12) 11.8 (10.6–13.6) 11 (10.5–13.6) 0.12\nPlatelet count (109/L) 264 (194–357) 282 (220–364) 244 (184–347) 162 (129–262) 0.12\nTotal bilirubin concentration (µmol/L) 8 (5.5–12) 8.5 (6–12) 11 (9–13) 7 (5.5–8) 0.72\nCreatinine (µmol/L) 81 (53–162) 71 (51–109) 81 (73–173) 101 (82–184) 0.15\nC-reactive protein (CRP) (mg/L) 157 (112–263) 155 (112–265) 112 (102–131) 112 (109–178) 0.03\nRatio of PaO2 to FiO2 152 (100–181) 164 (107–214) 120 (94–214) 136 (72–155) 0.25\nSAPS II score on day 1 42 (31–57) 35 (30–58) 42 (21–55) 43 (35–82) 0.55\nSOFA score on day 1 7 (2–11) 7 (4–10) 5 (2–10) 9 (2–12) 0.76\nData are presented as median (IQR: interquartiles), n (%). P values comparing Aspergillus colonization, invasive aspergillosis and no aspergillosis groups are tested by Kruskal–Wallis (continuous variables) or Chi-square test (categorical variables). Abbreviations: BMI: Body mass index; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment, PaO2: arterial oxygen tension."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T170","span":{"begin":138,"end":140},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T171","span":{"begin":182,"end":194},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T172","span":{"begin":281,"end":283},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T173","span":{"begin":305,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T174","span":{"begin":422,"end":424},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T175","span":{"begin":456,"end":458},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T176","span":{"begin":857,"end":864},"obj":"http://purl.obolibrary.org/obo/CLO_0054060"},{"id":"T177","span":{"begin":947,"end":953},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T178","span":{"begin":947,"end":953},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T179","span":{"begin":947,"end":953},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T180","span":{"begin":1094,"end":1099},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T181","span":{"begin":1094,"end":1099},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T182","span":{"begin":1094,"end":1099},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T183","span":{"begin":1094,"end":1099},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T184","span":{"begin":1127,"end":1129},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T185","span":{"begin":1155,"end":1158},"obj":"http://purl.obolibrary.org/obo/CLO_0054060"},{"id":"T186","span":{"begin":1193,"end":1195},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T187","span":{"begin":1241,"end":1244},"obj":"http://purl.obolibrary.org/obo/CLO_0054060"},{"id":"T188","span":{"begin":1258,"end":1263},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T189","span":{"begin":1264,"end":1268},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T190","span":{"begin":1607,"end":1609},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T191","span":{"begin":1697,"end":1700},"obj":"http://purl.obolibrary.org/obo/CLO_0001002"},{"id":"T192","span":{"begin":1774,"end":1778},"obj":"http://purl.obolibrary.org/obo/CLO_0001442"},{"id":"T193","span":{"begin":1781,"end":1783},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T194","span":{"begin":1836,"end":1839},"obj":"http://purl.obolibrary.org/obo/CLO_0001002"},{"id":"T195","span":{"begin":1842,"end":1844},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T196","span":{"begin":1955,"end":1958},"obj":"http://purl.obolibrary.org/obo/CLO_0054060"},{"id":"T197","span":{"begin":2017,"end":2020},"obj":"http://purl.obolibrary.org/obo/CLO_0054057"},{"id":"T198","span":{"begin":2043,"end":2045},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T199","span":{"begin":2107,"end":2109},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T200","span":{"begin":2135,"end":2137},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T201","span":{"begin":2174,"end":2176},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T202","span":{"begin":2266,"end":2274},"obj":"http://purl.obolibrary.org/obo/CLO_0008192"},{"id":"T203","span":{"begin":2304,"end":2316},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T204","span":{"begin":2373,"end":2379},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T205","span":{"begin":2435,"end":2439},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T206","span":{"begin":2566,"end":2571},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T207","span":{"begin":2598,"end":2606},"obj":"http://purl.obolibrary.org/obo/UBERON_0001637"},{"id":"T208","span":{"begin":2598,"end":2606},"obj":"http://www.ebi.ac.uk/efo/EFO_0000814"}],"text":"Table 3 Demographic characteristics and clinical and biological baseline characteristics.\nDemographic Characteristics All Patients (n = 45) No Aspergillosis (n = 30) Aspergillus Colonization (n = 8) Putative/Probable Invasive Aspergillosis (n = 7) p Value\nAge, years 60 (53–71) 59 (54–68) 53 (51–71) 70 (63–75) 0.14\nSexMen Women 32 (71.1)13 (28.9) 21 (70)9 (30) 7 (87.5)1 (12.5) 4 (57.1)3 (42.8) 0.42\nBMI 27 (24.4–31.4) 27.5 (24.7–32.3) 27 (25.2–30.7) 25.2 (23.2–26.4) 0.99\nCurrent smoking 3 (6.7) 2 (4.4) 0 1 (12.5) 0.54\nCoexisting conditions\nAny 31 (68.9) 19 (63) 6 (75) 6 (85.7) 0.47\nDiabetes 17 (37.8) 12 (40) 3 (37.5) 2 (28.6) 0.74\nHypertension 15 (33.3) 7 (23.3) 5 (62.5) 3 (42.9) 0.1\nSolid cancer 1 (2.2) 1 (3.3) 0 0 0.77\nHemopathy 2 (4.4) 1 (3.3) 0 1 (14.3) 0.54\nCardiovascular disease 3 (6.7) 3 (10) 2 (25) 2 (28.6) 0.34\nChronic obstructive pulmonary disease 0 0 0 0 -\nChronic kidney disease 4 (8.9) 2 (6.7) 1 (12.5) 1 (14.3) 0.83\nTemperature (°C) 38 (37–38.9) 37.5 (337–38.4) 38.2 (37.9–39) 38.2 (37.7–38.8) 0.29\nHeart rate (/min) 100 (80–110) 94 (80–110) 104 (100–110) 102 (85–119) 0.63\nSystolic pressure 94 (87–107) 93 (85–105) 103 (100–109) 90 (82–102) 0.34\nWhite blood cell count (109/L) 9.8 (6.8–12.9) 9.7 (6.9–13) 9.9 (7–10.7) 9.9 (6.7–12.9) 0.97\nNeutrophil count (109/L) 7.9 (4.5–10.8) 7 (4.9–10.5) 8.5 (5.2–8.6) 5.6 (3.5–10.4) 0.8\nLymphocyte count (109/L) 0.81 (0.58–1.11) 0.83 (0.53–1.14) 0.7 (0.63–1.1) 0.72 (0.58–0.81) 0.87\nHemoglobin (g/L) 10.8 (9.5–12.5) 10 (9.4–12) 11.8 (10.6–13.6) 11 (10.5–13.6) 0.12\nPlatelet count (109/L) 264 (194–357) 282 (220–364) 244 (184–347) 162 (129–262) 0.12\nTotal bilirubin concentration (µmol/L) 8 (5.5–12) 8.5 (6–12) 11 (9–13) 7 (5.5–8) 0.72\nCreatinine (µmol/L) 81 (53–162) 71 (51–109) 81 (73–173) 101 (82–184) 0.15\nC-reactive protein (CRP) (mg/L) 157 (112–263) 155 (112–265) 112 (102–131) 112 (109–178) 0.03\nRatio of PaO2 to FiO2 152 (100–181) 164 (107–214) 120 (94–214) 136 (72–155) 0.25\nSAPS II score on day 1 42 (31–57) 35 (30–58) 42 (21–55) 43 (35–82) 0.55\nSOFA score on day 1 7 (2–11) 7 (4–10) 5 (2–10) 9 (2–12) 0.76\nData are presented as median (IQR: interquartiles), n (%). P values comparing Aspergillus colonization, invasive aspergillosis and no aspergillosis groups are tested by Kruskal–Wallis (continuous variables) or Chi-square test (categorical variables). Abbreviations: BMI: Body mass index; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment, PaO2: arterial oxygen tension."}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":673,"end":685},"obj":"Phenotype"},{"id":"T12","span":{"begin":738,"end":744},"obj":"Phenotype"},{"id":"T13","span":{"begin":822,"end":844},"obj":"Phenotype"},{"id":"T14","span":{"begin":886,"end":923},"obj":"Phenotype"},{"id":"T15","span":{"begin":939,"end":961},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0012622"}],"text":"Table 3 Demographic characteristics and clinical and biological baseline characteristics.\nDemographic Characteristics All Patients (n = 45) No Aspergillosis (n = 30) Aspergillus Colonization (n = 8) Putative/Probable Invasive Aspergillosis (n = 7) p Value\nAge, years 60 (53–71) 59 (54–68) 53 (51–71) 70 (63–75) 0.14\nSexMen Women 32 (71.1)13 (28.9) 21 (70)9 (30) 7 (87.5)1 (12.5) 4 (57.1)3 (42.8) 0.42\nBMI 27 (24.4–31.4) 27.5 (24.7–32.3) 27 (25.2–30.7) 25.2 (23.2–26.4) 0.99\nCurrent smoking 3 (6.7) 2 (4.4) 0 1 (12.5) 0.54\nCoexisting conditions\nAny 31 (68.9) 19 (63) 6 (75) 6 (85.7) 0.47\nDiabetes 17 (37.8) 12 (40) 3 (37.5) 2 (28.6) 0.74\nHypertension 15 (33.3) 7 (23.3) 5 (62.5) 3 (42.9) 0.1\nSolid cancer 1 (2.2) 1 (3.3) 0 0 0.77\nHemopathy 2 (4.4) 1 (3.3) 0 1 (14.3) 0.54\nCardiovascular disease 3 (6.7) 3 (10) 2 (25) 2 (28.6) 0.34\nChronic obstructive pulmonary disease 0 0 0 0 -\nChronic kidney disease 4 (8.9) 2 (6.7) 1 (12.5) 1 (14.3) 0.83\nTemperature (°C) 38 (37–38.9) 37.5 (337–38.4) 38.2 (37.9–39) 38.2 (37.7–38.8) 0.29\nHeart rate (/min) 100 (80–110) 94 (80–110) 104 (100–110) 102 (85–119) 0.63\nSystolic pressure 94 (87–107) 93 (85–105) 103 (100–109) 90 (82–102) 0.34\nWhite blood cell count (109/L) 9.8 (6.8–12.9) 9.7 (6.9–13) 9.9 (7–10.7) 9.9 (6.7–12.9) 0.97\nNeutrophil count (109/L) 7.9 (4.5–10.8) 7 (4.9–10.5) 8.5 (5.2–8.6) 5.6 (3.5–10.4) 0.8\nLymphocyte count (109/L) 0.81 (0.58–1.11) 0.83 (0.53–1.14) 0.7 (0.63–1.1) 0.72 (0.58–0.81) 0.87\nHemoglobin (g/L) 10.8 (9.5–12.5) 10 (9.4–12) 11.8 (10.6–13.6) 11 (10.5–13.6) 0.12\nPlatelet count (109/L) 264 (194–357) 282 (220–364) 244 (184–347) 162 (129–262) 0.12\nTotal bilirubin concentration (µmol/L) 8 (5.5–12) 8.5 (6–12) 11 (9–13) 7 (5.5–8) 0.72\nCreatinine (µmol/L) 81 (53–162) 71 (51–109) 81 (73–173) 101 (82–184) 0.15\nC-reactive protein (CRP) (mg/L) 157 (112–263) 155 (112–265) 112 (102–131) 112 (109–178) 0.03\nRatio of PaO2 to FiO2 152 (100–181) 164 (107–214) 120 (94–214) 136 (72–155) 0.25\nSAPS II score on day 1 42 (31–57) 35 (30–58) 42 (21–55) 43 (35–82) 0.55\nSOFA score on day 1 7 (2–11) 7 (4–10) 5 (2–10) 9 (2–12) 0.76\nData are presented as median (IQR: interquartiles), n (%). P values comparing Aspergillus colonization, invasive aspergillosis and no aspergillosis groups are tested by Kruskal–Wallis (continuous variables) or Chi-square test (categorical variables). Abbreviations: BMI: Body mass index; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment, PaO2: arterial oxygen tension."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T190","span":{"begin":0,"end":90},"obj":"Sentence"},{"id":"T191","span":{"begin":91,"end":261},"obj":"Sentence"},{"id":"T192","span":{"begin":262,"end":326},"obj":"Sentence"},{"id":"T193","span":{"begin":327,"end":416},"obj":"Sentence"},{"id":"T194","span":{"begin":417,"end":494},"obj":"Sentence"},{"id":"T195","span":{"begin":495,"end":547},"obj":"Sentence"},{"id":"T196","span":{"begin":548,"end":569},"obj":"Sentence"},{"id":"T197","span":{"begin":570,"end":617},"obj":"Sentence"},{"id":"T198","span":{"begin":618,"end":672},"obj":"Sentence"},{"id":"T199","span":{"begin":673,"end":731},"obj":"Sentence"},{"id":"T200","span":{"begin":732,"end":774},"obj":"Sentence"},{"id":"T201","span":{"begin":775,"end":821},"obj":"Sentence"},{"id":"T202","span":{"begin":822,"end":885},"obj":"Sentence"},{"id":"T203","span":{"begin":886,"end":938},"obj":"Sentence"},{"id":"T204","span":{"begin":939,"end":1005},"obj":"Sentence"},{"id":"T205","span":{"begin":1006,"end":1093},"obj":"Sentence"},{"id":"T206","span":{"begin":1094,"end":1173},"obj":"Sentence"},{"id":"T207","span":{"begin":1174,"end":1251},"obj":"Sentence"},{"id":"T208","span":{"begin":1252,"end":1348},"obj":"Sentence"},{"id":"T209","span":{"begin":1349,"end":1439},"obj":"Sentence"},{"id":"T210","span":{"begin":1440,"end":1540},"obj":"Sentence"},{"id":"T211","span":{"begin":1541,"end":1627},"obj":"Sentence"},{"id":"T212","span":{"begin":1628,"end":1716},"obj":"Sentence"},{"id":"T213","span":{"begin":1717,"end":1807},"obj":"Sentence"},{"id":"T214","span":{"begin":1808,"end":1886},"obj":"Sentence"},{"id":"T215","span":{"begin":1887,"end":1984},"obj":"Sentence"},{"id":"T216","span":{"begin":1985,"end":2070},"obj":"Sentence"},{"id":"T217","span":{"begin":2071,"end":2147},"obj":"Sentence"},{"id":"T218","span":{"begin":2148,"end":2213},"obj":"Sentence"},{"id":"T219","span":{"begin":2214,"end":2272},"obj":"Sentence"},{"id":"T220","span":{"begin":2273,"end":2464},"obj":"Sentence"},{"id":"T221","span":{"begin":2465,"end":2484},"obj":"Sentence"},{"id":"T222","span":{"begin":2485,"end":2510},"obj":"Sentence"},{"id":"T223","span":{"begin":2511,"end":2554},"obj":"Sentence"},{"id":"T224","span":{"begin":2555,"end":2622},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 3 Demographic characteristics and clinical and biological baseline characteristics.\nDemographic Characteristics All Patients (n = 45) No Aspergillosis (n = 30) Aspergillus Colonization (n = 8) Putative/Probable Invasive Aspergillosis (n = 7) p Value\nAge, years 60 (53–71) 59 (54–68) 53 (51–71) 70 (63–75) 0.14\nSexMen Women 32 (71.1)13 (28.9) 21 (70)9 (30) 7 (87.5)1 (12.5) 4 (57.1)3 (42.8) 0.42\nBMI 27 (24.4–31.4) 27.5 (24.7–32.3) 27 (25.2–30.7) 25.2 (23.2–26.4) 0.99\nCurrent smoking 3 (6.7) 2 (4.4) 0 1 (12.5) 0.54\nCoexisting conditions\nAny 31 (68.9) 19 (63) 6 (75) 6 (85.7) 0.47\nDiabetes 17 (37.8) 12 (40) 3 (37.5) 2 (28.6) 0.74\nHypertension 15 (33.3) 7 (23.3) 5 (62.5) 3 (42.9) 0.1\nSolid cancer 1 (2.2) 1 (3.3) 0 0 0.77\nHemopathy 2 (4.4) 1 (3.3) 0 1 (14.3) 0.54\nCardiovascular disease 3 (6.7) 3 (10) 2 (25) 2 (28.6) 0.34\nChronic obstructive pulmonary disease 0 0 0 0 -\nChronic kidney disease 4 (8.9) 2 (6.7) 1 (12.5) 1 (14.3) 0.83\nTemperature (°C) 38 (37–38.9) 37.5 (337–38.4) 38.2 (37.9–39) 38.2 (37.7–38.8) 0.29\nHeart rate (/min) 100 (80–110) 94 (80–110) 104 (100–110) 102 (85–119) 0.63\nSystolic pressure 94 (87–107) 93 (85–105) 103 (100–109) 90 (82–102) 0.34\nWhite blood cell count (109/L) 9.8 (6.8–12.9) 9.7 (6.9–13) 9.9 (7–10.7) 9.9 (6.7–12.9) 0.97\nNeutrophil count (109/L) 7.9 (4.5–10.8) 7 (4.9–10.5) 8.5 (5.2–8.6) 5.6 (3.5–10.4) 0.8\nLymphocyte count (109/L) 0.81 (0.58–1.11) 0.83 (0.53–1.14) 0.7 (0.63–1.1) 0.72 (0.58–0.81) 0.87\nHemoglobin (g/L) 10.8 (9.5–12.5) 10 (9.4–12) 11.8 (10.6–13.6) 11 (10.5–13.6) 0.12\nPlatelet count (109/L) 264 (194–357) 282 (220–364) 244 (184–347) 162 (129–262) 0.12\nTotal bilirubin concentration (µmol/L) 8 (5.5–12) 8.5 (6–12) 11 (9–13) 7 (5.5–8) 0.72\nCreatinine (µmol/L) 81 (53–162) 71 (51–109) 81 (73–173) 101 (82–184) 0.15\nC-reactive protein (CRP) (mg/L) 157 (112–263) 155 (112–265) 112 (102–131) 112 (109–178) 0.03\nRatio of PaO2 to FiO2 152 (100–181) 164 (107–214) 120 (94–214) 136 (72–155) 0.25\nSAPS II score on day 1 42 (31–57) 35 (30–58) 42 (21–55) 43 (35–82) 0.55\nSOFA score on day 1 7 (2–11) 7 (4–10) 5 (2–10) 9 (2–12) 0.76\nData are presented as median (IQR: interquartiles), n (%). P values comparing Aspergillus colonization, invasive aspergillosis and no aspergillosis groups are tested by Kruskal–Wallis (continuous variables) or Chi-square test (categorical variables). Abbreviations: BMI: Body mass index; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment, PaO2: arterial oxygen tension."}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"598","span":{"begin":1887,"end":1905},"obj":"Gene"},{"id":"599","span":{"begin":1907,"end":1910},"obj":"Gene"},{"id":"600","span":{"begin":124,"end":132},"obj":"Species"},{"id":"601","span":{"begin":334,"end":339},"obj":"Species"},{"id":"602","span":{"begin":170,"end":181},"obj":"Species"},{"id":"603","span":{"begin":1808,"end":1818},"obj":"Chemical"},{"id":"604","span":{"begin":222,"end":244},"obj":"Disease"},{"id":"605","span":{"begin":618,"end":626},"obj":"Disease"},{"id":"606","span":{"begin":673,"end":685},"obj":"Disease"},{"id":"607","span":{"begin":738,"end":744},"obj":"Disease"},{"id":"608","span":{"begin":775,"end":784},"obj":"Disease"},{"id":"609","span":{"begin":822,"end":844},"obj":"Disease"},{"id":"610","span":{"begin":886,"end":923},"obj":"Disease"},{"id":"611","span":{"begin":939,"end":961},"obj":"Disease"},{"id":"616","span":{"begin":2292,"end":2303},"obj":"Species"},{"id":"617","span":{"begin":2607,"end":2613},"obj":"Chemical"},{"id":"618","span":{"begin":2318,"end":2340},"obj":"Disease"},{"id":"619","span":{"begin":2348,"end":2361},"obj":"Disease"}],"attributes":[{"id":"A598","pred":"tao:has_database_id","subj":"598","obj":"Gene:1401"},{"id":"A599","pred":"tao:has_database_id","subj":"599","obj":"Gene:1401"},{"id":"A600","pred":"tao:has_database_id","subj":"600","obj":"Tax:9606"},{"id":"A601","pred":"tao:has_database_id","subj":"601","obj":"Tax:9606"},{"id":"A602","pred":"tao:has_database_id","subj":"602","obj":"Tax:746128"},{"id":"A603","pred":"tao:has_database_id","subj":"603","obj":"MESH:D003404"},{"id":"A604","pred":"tao:has_database_id","subj":"604","obj":"MESH:D055744"},{"id":"A605","pred":"tao:has_database_id","subj":"605","obj":"MESH:D003920"},{"id":"A606","pred":"tao:has_database_id","subj":"606","obj":"MESH:D006973"},{"id":"A607","pred":"tao:has_database_id","subj":"607","obj":"MESH:D009369"},{"id":"A609","pred":"tao:has_database_id","subj":"609","obj":"MESH:D002318"},{"id":"A610","pred":"tao:has_database_id","subj":"610","obj":"MESH:D029424"},{"id":"A611","pred":"tao:has_database_id","subj":"611","obj":"MESH:D051436"},{"id":"A616","pred":"tao:has_database_id","subj":"616","obj":"Tax:746128"},{"id":"A617","pred":"tao:has_database_id","subj":"617","obj":"MESH:D010100"},{"id":"A618","pred":"tao:has_database_id","subj":"618","obj":"MESH:D055744"},{"id":"A619","pred":"tao:has_database_id","subj":"619","obj":"MESH:D001228"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 3 Demographic characteristics and clinical and biological baseline characteristics.\nDemographic Characteristics All Patients (n = 45) No Aspergillosis (n = 30) Aspergillus Colonization (n = 8) Putative/Probable Invasive Aspergillosis (n = 7) p Value\nAge, years 60 (53–71) 59 (54–68) 53 (51–71) 70 (63–75) 0.14\nSexMen Women 32 (71.1)13 (28.9) 21 (70)9 (30) 7 (87.5)1 (12.5) 4 (57.1)3 (42.8) 0.42\nBMI 27 (24.4–31.4) 27.5 (24.7–32.3) 27 (25.2–30.7) 25.2 (23.2–26.4) 0.99\nCurrent smoking 3 (6.7) 2 (4.4) 0 1 (12.5) 0.54\nCoexisting conditions\nAny 31 (68.9) 19 (63) 6 (75) 6 (85.7) 0.47\nDiabetes 17 (37.8) 12 (40) 3 (37.5) 2 (28.6) 0.74\nHypertension 15 (33.3) 7 (23.3) 5 (62.5) 3 (42.9) 0.1\nSolid cancer 1 (2.2) 1 (3.3) 0 0 0.77\nHemopathy 2 (4.4) 1 (3.3) 0 1 (14.3) 0.54\nCardiovascular disease 3 (6.7) 3 (10) 2 (25) 2 (28.6) 0.34\nChronic obstructive pulmonary disease 0 0 0 0 -\nChronic kidney disease 4 (8.9) 2 (6.7) 1 (12.5) 1 (14.3) 0.83\nTemperature (°C) 38 (37–38.9) 37.5 (337–38.4) 38.2 (37.9–39) 38.2 (37.7–38.8) 0.29\nHeart rate (/min) 100 (80–110) 94 (80–110) 104 (100–110) 102 (85–119) 0.63\nSystolic pressure 94 (87–107) 93 (85–105) 103 (100–109) 90 (82–102) 0.34\nWhite blood cell count (109/L) 9.8 (6.8–12.9) 9.7 (6.9–13) 9.9 (7–10.7) 9.9 (6.7–12.9) 0.97\nNeutrophil count (109/L) 7.9 (4.5–10.8) 7 (4.9–10.5) 8.5 (5.2–8.6) 5.6 (3.5–10.4) 0.8\nLymphocyte count (109/L) 0.81 (0.58–1.11) 0.83 (0.53–1.14) 0.7 (0.63–1.1) 0.72 (0.58–0.81) 0.87\nHemoglobin (g/L) 10.8 (9.5–12.5) 10 (9.4–12) 11.8 (10.6–13.6) 11 (10.5–13.6) 0.12\nPlatelet count (109/L) 264 (194–357) 282 (220–364) 244 (184–347) 162 (129–262) 0.12\nTotal bilirubin concentration (µmol/L) 8 (5.5–12) 8.5 (6–12) 11 (9–13) 7 (5.5–8) 0.72\nCreatinine (µmol/L) 81 (53–162) 71 (51–109) 81 (73–173) 101 (82–184) 0.15\nC-reactive protein (CRP) (mg/L) 157 (112–263) 155 (112–265) 112 (102–131) 112 (109–178) 0.03\nRatio of PaO2 to FiO2 152 (100–181) 164 (107–214) 120 (94–214) 136 (72–155) 0.25\nSAPS II score on day 1 42 (31–57) 35 (30–58) 42 (21–55) 43 (35–82) 0.55\nSOFA score on day 1 7 (2–11) 7 (4–10) 5 (2–10) 9 (2–12) 0.76\nData are presented as median (IQR: interquartiles), n (%). P values comparing Aspergillus colonization, invasive aspergillosis and no aspergillosis groups are tested by Kruskal–Wallis (continuous variables) or Chi-square test (categorical variables). Abbreviations: BMI: Body mass index; SAPS II: Simplified Acute Physiology Score II; SOFA: Sequential Organ Failure Assessment, PaO2: arterial oxygen tension."}